We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Improving antibody affinity through in vitro mutagenesis in complementarity determining regions.
- Authors
Wei Ye; Xiaoyu Liu; Ruiting He; Liming Gou; Ming Lu; Gang Yang; Jiaqi Wen; Xufei Wang; Fang Liu; Sujuan Ma; Weifeng Qian; Shaochang Jia; Tong Ding; Luan Sun; Wei Gao
- Abstract
High-affinity antibodies are widely used in diagnostics and for the treatment of human diseases. However, most antibodies are isolated from semi-synthetic libraries by phage display and do not possess in vivo affinity maturation, which is triggered by antigen immunization. It is therefore necessary to engineer the affinity of these antibodies by way of in vitro assaying. In this study, we optimized the affinity of two human monoclonal antibodies which were isolated by phage display in a previous related study. For the 42A1 antibody, which targets the liver cancer antigen glypican-3, the variant T57H in the second complementarity-determining region of the heavy chain (CDR-H2) exhibited a 2.6-fold improvement in affinity, as well as enhanced cell-binding activity. For the I4A3 antibody to severe acute respiratory syndrome coronavirus 2, beneficial single mutations in CDR-H2 and CDR-H3 were randomly combined to select the best synergistic mutations. Among these, the mutation S53PS98T improved binding affinity (about 3.7 fold) and the neutralizing activity (about 12 fold) compared to the parent antibody. Taken together, single mutations of key residues in antibody CDRs were enough to increase binding affinity with improved antibody functions. The mutagenic combination of key residues in different CDRs creates additive enhancements. Therefore, this study provides a safe and effective in vitro strategy for optimizing antibody affinity.
- Subjects
SARS-CoV-2; MUTAGENESIS
- Publication
Journal of Biomedical Research, 2022, Vol 36, Issue 3, p155
- ISSN
1674-8301
- Publication type
Article
- DOI
10.7555/JBR.36.20220003